Equity Details
Price & Market Data
Price: $14.44
Daily Change: -$0.44 / 3.05%
Daily Range: $14.22 - $15.00
Market Cap: $1,605,530,368
Daily Volume: 946,175
Performance Metrics
1 Week: -12.11%
1 Month: -12.33%
3 Months: -3.02%
6 Months: 17.30%
1 Year: 213.9%
YTD: 19.54%
About Amylyx Pharmaceuticals, Inc. (AMLX)
A concise financial summary for Amylyx Pharmaceuticals, Inc. (AMLX). Priced at 14.44, it shows a daily movement of -$0.44 / 3.05%. Market cap: 1,605,530,368. Performance over 1-week and 1-year are key takeaways.
Company Details
Employees: 136
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.